This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Source: Motley Fool
2026-03-08 17:48:00 ET
Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ: NTLA) , fits the bill.
Intellia is a mid-cap biotech company specializing in gene editing and developing medicines for diseases for which few exist. The drugmaker has already performed exceptionally well this year, with shares up 47%. Should investors consider purchasing shares of Intellia Therapeutics after this run?
Image source: Getty Images.
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
7.7% G/L:
$13.98 Last:
1,764,325 Volume:
$13.25 Open:
NTLA Latest News
March 03, 2026 07:30:00 am
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 02, 2026 07:30:00 am
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
